Weakly hormone receptor- positive breast cancer and use of adjuvant hormonal therapy

Current Oncology

Volumn 20, Issue 6, 2013, Pages

  Lin, Cassandra M ^a   Jaswal, Jasbir ^a   Vandenberg, Theodore ^a   Tuck, Alan ^a   Brackstone, Muriel ^a  

^a WESTERN UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; ESTROGEN RECEPTOR; HORMONE RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; PREDICTIVE VALUE; RECEPTOR BINDING ASSAY;

EID: 84890012438     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.20.1598     Document Type: Letter

References (5)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010;28:2784-95. [Erratum in: J Clin Oncol 2010;28:3543]
3. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009;20:1319-29.
4. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-81.
5. Morgan DA, Refalo NA, Cheung KL. Strength of erpositivity in relation to survival in er-positive breast cancer treated by adjuvant tamoxifen as sole systemic therapy. Breast 2011;20:215-19.